previously treated patients
Showing 1 - 25 of >10,000
Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Solid Tumor, Adult
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 13, 2023
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1
Not yet recruiting
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Ivosidenib 500mg
- Placebo
- (no location specified)
Nov 7, 2023
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)
Not yet recruiting
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma Metastatic
- (no location specified)
Oct 10, 2023
Participants Previously Treated With Century Therapeutics
Not yet recruiting
- Hematological Malignancy
- Solid Tumor Malignancy
- No Intervention
- (no location specified)
Mar 3, 2023
Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- +2 more
- Enfortumab vedotin
-
Kansas City, KansasUniversity of Kansas Cancer Center
Jun 23, 2023
Peri-implant Mucositis, Peri-Implantitis Trial in Pittsburgh (Induction of experimental peri-implant mucositis, Resolution of
Recruiting
- Peri-implant Mucositis
- Peri-Implantitis
- Induction of experimental peri-implant mucositis
- Resolution of experimental peri-implant mucositis
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh School of Dental Medicine
Sep 25, 2023
Kaposi Sarcoma, Classic Kaposi Sarcoma, Refractory Kaposi Sarcoma Trial (Pembrolizumab + Lenvatinib)
Not yet recruiting
- Kaposi Sarcoma
- +2 more
- Pembrolizumab + Lenvatinib
- (no location specified)
Apr 27, 2023
Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Gastric Cancer Metastatic to Liver
- Cryoablation
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 6, 2023
Soft Tissue Sarcoma Trial (ADI PEG20, Placebo)
Not yet recruiting
- Soft Tissue Sarcoma
- ADI PEG20
- Placebo
- (no location specified)
Jan 31, 2023
Diabetes, Lipodystrophy, Hyperlipidemia Trial run by the NIDDK (Metreleptin)
Active, not recruiting
- Diabetes
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 21, 2023
Primary Immune Thrombocytopenia (ITP) Trial (Ianalumab)
Not yet recruiting
- Primary Immune Thrombocytopenia (ITP)
- Ianalumab
- (no location specified)
Jun 5, 2023
Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)
Recruiting
- Advanced Biliary Tract Cancer
- Sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 22, 2023
Nasopharyngeal Carcinoma Trial in Beijing (Donafenib)
Recruiting
- Nasopharyngeal Carcinoma
-
Beijing, Beijing, ChinaCancer Hospital of Medical College
Nov 28, 2022
Lipodystrophy, Diabetes, Hyperlipidemia Trial run by the NIDDK (Metreleptin)
Recruiting
- Lipodystrophy
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment
Not yet recruiting
- Long Term Efficacy and Safety
- Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
- Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
- (no location specified)
Jun 30, 2023
Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases Trial (Renal Autologous Cell Therapy (REACT))
Not yet recruiting
- Diabetic Kidney Disease
- +2 more
- Renal Autologous Cell Therapy (REACT)
- (no location specified)
Jan 11, 2023
NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)
Not yet recruiting
- NSCLC
- Non-small Cell Lung Cancer
- Apatinib + Fluzoparib
- Apatinib + Fluzoparib + Adebrelimab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Jun 27, 2023
Participants Previously Treated With EB-101 for Treatment of
Enrolling by invitation
- RDEB
- EB-101
-
Redwood City, California
- +1 more
Feb 1, 2023